Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P‐Glycoprotein
Authors:
- 2 January 2021
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (6) , 799-805
Abstract
Nadolol is a hydrophilic and nonselective β‐adrenoceptor blocker with a bioavailability of 30%, relatively longer half‐life, negligible metabolism, and predominant renal excretion. Previous studies have reported that nadolol is a substrate of P‐glycoprotein, and the coadministration with itraconazole, a typical P‐glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol. In this study, we assessed whether measurements of urinary‐excreted nadolol can be an alternative method of plasma pharmacokinetics for P‐glycoprotein‐mediated drug interactions in humans. We reanalyzed the pooled data set of plasma concentration and urinary excretion of nadolol from our previous clinical studies in a total of 32 healthy Japanese adults. The area under the plasma concentration‐time curve from 0 to infinity (AUC0‐∞) of nadolol in individual subjects was significantly correlated with the maximum plasma concentration (r = 0.80, P < .01) and the cumulative amount excreted into urine (Ae) at 4 (r = 0.51, P = .01), 8 (r = 0.63, P < .01), 24 (r = 0.75, P < .01), and 48 (r = 0.77, P < .01) hours. Significant correlations were also observed between the AUC and Ae during the same respective periods. In the drug interactions of nadolol with itraconazole, rifampicin, a well‐known P‐glycoprotein inducer, or grapefruit juice, there were significant correlations between the differences in AUC0‐48 and those in Ae, 0‐48 from the controls in individual subjects. These results suggest that the measurements of urinary excretion of nadolol can be employed as a sensitive and reliable alternative to plasma pharmacokinetics for the evaluation of P‐glycoprotein‐mediated drug interactions.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP17K17983)
This publication has 31 references indexed in Scilit:
- Clinical Aspects of Transporter‐Mediated Drug–Drug InteractionsClinical Pharmacology & Therapeutics, 2019
- The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3Molecular Pharmaceutics, 2016
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)Pharmaceutical Research, 2015
- BDDCS Applied to Over 900 DrugsThe AAPS Journal, 2011
- The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humansPharmacogenetics and Genomics, 2011
- Species Difference in the Effect of Grapefruit Juice on Intestinal Absorption of Talinolol between Human and RatThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Biopharmaceutics Classification of Selected β-Blockers: Solubility and Permeability Class MembershipMolecular Pharmaceutics, 2007
- Naringin is a Major and Selective Clinical Inhibitor of Organic Anion-Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit JuiceClinical Pharmacology & Therapeutics, 2007
- Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphismsBritish Journal of Clinical Pharmacology, 2006
- NadololDrugs, 1980